Subotic U, Hosie S, Waag K L, Reinshagen K
Kinderchirurgie, Inselspital, Universität Bern.
Klin Padiatr. 2008 Jul-Aug;220(4):248-52. doi: 10.1055/s-2008-1073158.
The therapeutic gold standard of cystic hygroma is its complete resection. Because of its growth pattern and its main location in the head and neck region complete resection is not always possible. An alternative is the local injection of Picibanil, but only few cases have been published about its use in infants.
PATIENTS/METHOD: We retrospectively analyzed the data of 8 infants (age: 2 weeks-12 months) who got Picibanil therapy because of cystic hygroma in the time period 2002 until 2006. Follow up ranged from 3 months up to 3 years.
During the postoperative period all patients had local swelling, in 4 cases accompanied with local inflammation and fever. Tumor reduction of >50% was obtained in 7 of 8 patients.
Local injection of Picibanil in infants with cystic hygroma seems to be a safe alternative to surgical therapy, especially when complete tumor resection means damage of important neighbouring structures. Prospective trials are necessary to confirm the better outcome after therapy with Picibanil compare to primary surgery.
淋巴管瘤的治疗金标准是完整切除。由于其生长方式以及主要位于头颈部区域,完整切除并非总是可行。另一种选择是局部注射博来霉素,但关于其在婴儿中的应用仅有少数病例报道。
患者/方法:我们回顾性分析了2002年至2006年期间因淋巴管瘤接受博来霉素治疗的8例婴儿(年龄:2周 - 12个月)的数据。随访时间为3个月至3年。
术后所有患者均出现局部肿胀,4例伴有局部炎症和发热。8例患者中有7例肿瘤缩小超过50%。
对于患有淋巴管瘤的婴儿,局部注射博来霉素似乎是手术治疗的一种安全替代方法,尤其是当完整切除肿瘤意味着损害重要相邻结构时。需要进行前瞻性试验以证实与初次手术相比,博来霉素治疗后的效果更佳。